How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Acute Renal Failure (Arf) (Acute Kidney Injury) Market
- By Etiology: Prerenal Acute Kidney Injury, Intrinsic (Intrarenal) Acute Kidney Injury, Postrenal Acute Kidney Injury
- By Treatment Modality: Renal Replacement Therapy (RRT), Pharmacological Treatment, Supportive Care
- By Renal Replacement Therapy Type: Intermittent Hemodialysis (IHD), Continuous Renal Replacement Therapy (CRRT), Peritoneal Dialysis
- By Patient Setting: Intensive Care Unit (ICU) Patients, General Hospitalized Patients, Outpatient Management
- By Severity Stage: Stage 1 AKI, Stage 2 AKI, Stage 3 AKI
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Prerenal Acute Kidney Injury leads By Etiology at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.171 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.179 →
Full report · locked preview
Everything inside the Acute Renal Failure (Arf) (Acute Kidney Injury) Market report
A complete, evidence-based study - 12 chapters and 119 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Etiology 3
Treatment Modality 3
Renal Replacement Therapy Type 3
Patient Setting 3
Severity Stage 3
Companies profiled
Fresenius Medical Care AG & Co. KGaA
Baxter International Inc.
B. Braun Melsungen AG
Nipro Corporation
NxStage Medical
Inc. (a Fresenius company)
Medtronic plc
Asahi Kasei Corporation
Gambro (a part of Baxter)
Toray Medical Co. Ltd.
Hospal Group
Outset Medical Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Fresenius Medical Care AG & Co. KGaA
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Baxter International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →B. Braun Melsungen AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Nipro Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →NxStage Medical
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Inc. (a Fresenius company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Asahi Kasei Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Gambro (a part of Baxter)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Toray Medical Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Hospal Group
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Outset Medical Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Renal Solutions Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Medica S.p.A.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Nikkiso Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Hemocleanse
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,960M by 2033 · 8.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Prerenal Acute Kidney Injury63.0
- Intrinsic (Intrarenal) Acute Kidney Injury20.6
- Postrenal Acute Kidney Injury16.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$337.1M → $611.5M · 7.7%
Europe$234.9M → $412.7M · 7.3%
Asia Pacific$214.5M → $389.9M · 7.8%
Latin America$132.8M → $240.2M · 7.7%
Middle East and Africa$102.2M → $209.6M · 9.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.442026
8.452027
8.472028
8.472029
8.482030
8.492031
8.502032
8.512033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Fresenius Medical Care AG & Co. KGaA18.9
- Baxter International Inc.17.6
- B. Braun Melsungen AG11.6
- Nipro Corporation6.7
- NxStage Medical12.0
- Inc. (a Fresenius company)5.1
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Etiology15.8%
Treatment Modality14.3%
Renal Replacement Therapy Type29.1%
Patient Setting19.8%
Severity Stage20.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.8
- Europe22.1
- Asia Pacific20.9
- Latin America12.9
- Middle East and Africa11.2
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Fresenius Medical Care AG & Co. KGaA | 84 | 97 | 93 | 94 | 76 | 87 | 89 |
| Baxter International Inc. | 82 | 77 | 76 | 75 | 79 | 76 | 78 |
| B. Braun Melsungen AG | 72 | 71 | 84 | 82 | 64 | 68 | 74 |
| Nipro Corporation | 72 | 74 | 75 | 74 | 63 | 74 | 72 |
| NxStage Medical | 74 | 69 | 63 | 53 | 74 | 76 | 68 |
| Inc. (a Fresenius company) | 69 | 56 | 63 | 67 | 62 | 48 | 61 |
| Medtronic plc | 40 | 60 | 59 | 51 | 45 | 51 | 51 |
| Asahi Kasei Corporation | 41 | 37 | 55 | 59 | 36 | 54 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Fresenius Medical Care AG & Co. KGaA
- Baxter International Inc.
- B. Braun Melsungen AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Fresenius Medical Care AG & Co. KGaA | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Baxter International Inc. | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| B. Braun Melsungen AG | ✓ | ✓ | ◐ | ✓ | ◐ | ✓ |
| Nipro Corporation | ◐ | ◐ | ✓ | ✓ | ◐ | ◐ |
| NxStage Medical | ✓ | ✓ | ◐ | − | ✓ | ✓ |
| Inc. (a Fresenius company) | ◐ | − | ◐ | ✓ | − | − |
| Medtronic plc | − | ◐ | ◐ | − | − | − |
| Asahi Kasei Corporation | − | − | ◐ | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Fresenius Medical Care AG & Co. KGaA89
2Baxter International Inc.78
3B. Braun Melsungen AG74
4Nipro Corporation72
5NxStage Medical68
6Inc. (a Fresenius company)61
7Medtronic plc51
8Asahi Kasei Corporation47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Fresenius Medical Care AG & Co. KGaABaxter International Inc.
Challenger3
Strong scale, closing on the leaders.
B. Braun Melsungen AGNipro CorporationNxStage Medical
Contender1
Focused players with pockets of strength.
Inc. (a Fresenius company)
Niche2
Specialists in a single segment or region.
Medtronic plcAsahi Kasei Corporation
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Etiology in North America, then scale across Acute Renal Failure (Arf) (Acute Kidney Injury) Market — a $97M beachhead inside a $1.36B market.
Beachhead (SOM)$97Mobtainable near-term
Serviceable (SAM)$525Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Prerenal Acute Kidney Injury
Best fit — highest urgency & budget in Etiology.
Economic buyer79 fit
Intrinsic (Intrarenal) Acute Kidney Injury
Strong fit — clear ROI and a fast path to value.
End user69 fit
Postrenal Acute Kidney Injury
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Etiology in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Treatment Modality & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Renal Replacement Therapy Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel29%
Digital / self-serve18%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Etiology leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Acute Renal Failure (Arf) (Acute Kidney Injury) Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified46%
Sales qualified23%
Evaluation15%
Closed-won5%
$12.7KCAC
$63KLTV
5.0:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Acute Renal Failure (Arf) (Acute Kidney Injury) Market is a durable-growth opportunity — $2.08B by 2033, compounding at 7.3%.
TAM · 2025$1.18Btoday
TAM · 2033$2.08Bforecast
CAGR7.3%2027–2033
Cumulative$14.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.08BTotal addressable market
SAM$730MServiceable available market
SOM$135MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.3% CAGR
Demand compounds through 2033, outpacing GDP across Etiology.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Etiology moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.08BLarge & growingTAM by 2033 at 7.3% CAGR
$730MServiceable nowreachable with today’s model
$135MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.62BBear4.8% CAGR
$2.08BBase7.3% CAGR
$2.66BBull9.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Treatment Modality optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Acute Renal Failure (Arf) (Acute Kidney Injury) Market — a $2.16B market by 2033. Plan: grow share from 7.8% to 15.8%.
Market size · 2033$2.16Btotal addressable
Market CAGR3.3%2027–2033
Target share15.8%from 7.8% today
Revenue ambition$341Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.8% | 15.8% | At risk |
| Revenue | $170M | $341M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 36.3% | 39.8% | At risk |
| Customer retention | 89.8% | 92.7% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Etiology
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Treatment Modality capability
A defensible second engine — invest in Treatment Modality to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Etiology share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Treatment Modality
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $39M capacity & capability investment
- Greenlight bolt-on M&A in Treatment Modality
- Authorise North America expansion plan
- Fund R&D program for Etiology leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeAhead
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Acute Renal Failure (Arf) (Acute Kidney Injury) Market conversation — a $5.94B market you can size, segment and defend in minutes.
Market size · 2033$5.94Btotal opportunity
Growth5.0%CAGR to 2033
Addressable buyers1,372+accounts in scope
Typical ROI7.2×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Etiology
Goal Grow share in Etiology
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.2×return on cost, year one
< 3 mopayback period
$58K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Fresenius Medical Care AG & Co. KGaABaxter International Inc.B. Braun Melsungen AGNipro CorporationNxStage MedicalInc. (a Fresenius company)Medtronic plcAsahi Kasei Corporation+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Acute Renal Failure (Arf) (Acute Kidney Injury) Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Acute Renal Failure (Arf) (Acute Kidney Injury) Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Acute Renal Failure (ARF) Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportAcute Respiratory Distress Syndrome (ARDS) Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportAcute Respiratory Distress Syndrome Drug Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportAcute Respiratory Distress Syndrome Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportAcuum Deposition Systems Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reporta-Cyanoacrylate Adhesive Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportAd Converter Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportAd Exchanges Market
Market size, share, segmentation and regional forecast.
$923M market · 2025 base year
View reportAd Fraud Countermeasure Tools Market
Market size, share, segmentation and regional forecast.
$435M market · 2025 base year
View reportAd Spending Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportAD-67 Antidote CAS 71526-07-3 Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportADAMANTAN-1-YL-ACETIC ACID HYDRAZIDE CAS 19026-80-3 Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.